Kardiologie up2date 2009; 5(4): 296-301
DOI: 10.1055/s-0029-1243850
Hotline – Risikofaktoren

© Georg Thieme Verlag KG Stuttgart · New York

Homozystein: Risikofaktor oder Risikoindikator bei Gefäßerkrankungen?

Tanja  B.  Grammer, Tatjana  Stojakovic, Rüdiger  Siekmeier, Winfried  März
Further Information

Publication History

Publication Date:
23 December 2009 (online)


Elevated homocysteine has been shown to be associated with coronary heart disease, stroke, peripheral arterial occlusion and venous thromboembolism. High serum concentrations are found in individuals with genetic variants (e.g. MTHFR polymorphism), in folic acid deficiency, vitamin B12 -, and vitamin B6-deficiency, hypothyreosis, alcoholism, malignancy, and due to special drug therapy. Recent data from clinical trials demonstrated a significant decrease in serum concentrations of homocysteine during treatment with folic acid, vitamin B12 and vitamin B6, but there were no effects on clinical outcomes, like coronary artery disease, stroke, or peripheral vascular disease. Therefore, at present, elevated homocysteine should have the following practical implications: Hyperhomocysteinemia may be a marker of vitamin deficiency. Hence the causes of elevated homocysteine should be identified. Lowering homocysteine for the purpose of reducing cardiovascular risk cannot be recommended so far. Therefore, in the case of elevated homocysteine, the therapeutic focus should concentrate on the classical, modifiable risk factors (e.g. LDL-cholesterin, blood pressure).


Dr. med. univ. Tanja B. Grammer

Synlab Medizinisches Versorgungszentrum für Labordiagnostik Heidelberg

Postfach 104129
69031 Heidelberg

Email: tanja.grammer@synlab.de